UBT251 triple agonist shows weight reduction in phase 2 trial

Key details

UBT251, a GLP-1, GIP and glucagon receptor agonist, produced weight reduction in a phase 2 trial, and the authors say the results support phase 3 evaluation.

A study of UBT251 was published in Cell Metabolism, with the tracker's latest record dated October 7, 2026. It was a multicenter, randomized phase 2 trial in adults with overweight or obesity. UBT251 is a triple GLP-1, GIP and glucagon receptor agonist. The study authors say the results support phase 3 evaluation.

UBT251 is described as a novel agonist of three receptors: GLP-1, GIP and glucagon. According to the published record, UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile in adults with overweight or obesity. The authors say the results support phase 3 evaluation.

This is a phase 2 trial, and the study supports phase 3 evaluation. The record gives no approval information, so UBT251 should not be considered an approved drug. If you have questions about how a new drug like this might fit into your own treatment, that conversation belongs with your doctor.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.